版本:
中国

BRIEF-Resverlogix announces receipt of notice of allowance from the U.S. Patent And Trademark Office

March 15 Resverlogix Corp

* Resverlogix announces receipt of notice of allowance from the united states patent and trademark office

* Resverlogix -receipt of notice of allowance from uspto for patent claims covering use of apabetalone in combination with rosuvastatin in united states

* Resverlogix corp says rosuvastatin was exclusively marketed by astrazeneca under trade name crestor until its patent expired in 2016 Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐